July 14, 2014
Biotechnology Industry Organization and The Pharmaceutical Research and Manufacturers of America have told the Federal Circuit that its recent decision in a lawsuit over flu drug Tamiflu expanded the double-patent doctrine at a time that the doctrine is increasingly irrelevant because of changes in federal patent laws.
April 22, 2014
The Federal Circuit ruled Tuesday that a patent can be rendered invalid for double-patenting based on a patent that expires before it, expanding the double-patenting doctrine and giving Natco Pharma Ltd. another shot at invalidating Gilead Sciences Inc.'s patent on the flu drug Tamiflu.